Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIS-trial
2022-502776-22-00Phase 3Authorised
- Sponsor
- Region Uppsala
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anaemia comparing Ferric carboxymaltose with Placebo (2 arms). Planned start Mar 2024; status: authorised.
02
Drugs
ferric carboxymaltose
03
Conditions
anaemia
Beyond the preview
Go deeper on 2022-502776-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502776-22-00.